Top

Arsanis, Inc. scientists and their collaborators at Adimab, LLC have described a unique monoclonal antibody with the potential to treat Staphylococcus aureus (S. aureus) infections through the simultaneous neutralization of multiple key toxins produced by S. aureus, including alpha-hemolysin and four additional leukocidins. The findings are published online this week in the journal mAb and demonstrate superior in vitro potency compared to antibodies targeting alpha-hemolysin alone. The mAb also shows high protective efficacy from lethal S. aureus infections in several animal models.

View Document